Modality
Cell Therapy
MOA
CD47i
Target
Tau
Pathway
Wnt
MCCRett
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
May 2023
→ May 2027
Phase 2Current
NCT08960202
386 pts·Rett
2023-05→2027-05·Recruiting
386 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-221.1y awayPh2 Data· Rett
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2
Recruit…
Catalysts
Ph2 Data
2027-05-22 · 1.1y away
Rett
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08960202 | Phase 2 | Rett | Recruiting | 386 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| AMG-7379 | Amgen | Preclinical | DLL3 |